Ret Proto-Oncogene Antikörper (AA 29-304)

Produktnummer ABIN6719502

Dieses Anti-Ret Proto-Oncogene-Antikörper ist ein Kaninchen Polyklonal-Antikörper zur Detektion von Ret Proto-Oncogene in WB, ELISA und IHC. Geeignet für Human, Maus und Ratte.

Kurzübersicht für Ret Proto-Oncogene Antikörper (AA 29-304) (ABIN6719502)

Target: Ret Proto-Oncogene (RET)

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Ret Proto-Oncogene Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Produktdetails anti-Ret Proto-Oncogene Antikörper

Bindungsspezifität: AA 29-304

Verwendungszweck: Anti-RET Antibody Picoband®

Kreuzreaktivität (Details): No cross-reactivity with other proteins.

Produktmerkmale: Anti-RET Antibody Picoband® (ABIN6719502). Tested in ELISA, IHC, WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Aufreinigung: Immunogen affinity purified.

Immunogen: E.coli-derived human RET recombinant protein (Position: L29-V304).

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot, 0.1-0.5 μg/mL
Immunohistochemistry (Paraffin-embedded Section), 0.5-1 μg/mL
ELISA, 0.1-0.5 μg/mL
1. Ceccherini I, Bocciardi R, Luo Y, et al. (1993). "Exon structure and flanking intronic sequences of the human RET proto-oncogene". Biochem. Biophys. Res. Commun. 196 (3): 1288-1295. 2. Knowles PP, Murray-Rust J, Kjaer S, et al. (2006). "Structure and chemical inhibition of the RET tyrosine kinase domain". J. Biol. Chem.281 (44): 33577-87.

Kommentare:

Tested Species: In-house tested species with positive results. By Heat: Boiling the paraffin sections in 10mM citrate buffer, pH6.0, for 20mins is required for the staining of formalin/paraffin sections. Other applications have not been tested. Optimal dilutions should be determined by end users.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Konzentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Details zu Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Andere Bezeichnung: RET

Hintergrund:

Synonyms: Proto-oncogene tyrosine-protein kinase receptor Ret, Cadherin family member 12, Proto-oncogene c-Ret, RET, CDHF12, CDHR16, PTC, RET51

Tissue Specificity: Activated T-cells. Highly expressed on tonsillar T-cells, which are closely associated with B-cells in the apical light zone of germinal centers, the site of terminal B- cell maturation. Expressed at lower levels in thymus, lung, lymph node and peripheral blood leukocytes. Expressed in the medulla of fetal and newborn thymus.

Background: The RET proto-oncogene encodes a receptor tyrosine kinase for members of the glial cell line-derived neurotrophic factor (GDNF) family of extracellular signalling molecules. Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to the encoded receptor stimulates receptor dimerization and activation of downstream signaling pathways that play a role in cell differentiation, growth, migration and survival. The encoded receptor is important in development of the nervous system, and the development of organs and tissues derived from the neural crest. This proto-oncogene can undergo oncogenic activation through both cytogenetic rearrangement and activating point mutations. Mutations in this gene are associated with Hirschsprung disease and central hypoventilation syndrome and have been identified in patients with renal agenesis.

Molekulargewicht: 170 kDa

Gen-ID: 5979

UniProt: P07949

Pathways: RTK Signalweg, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation